» Articles » PMID: 19910050

Peptide Binding to MHC Class I and II Proteins: New Avenues from New Methods

Overview
Journal Mol Immunol
Date 2009 Nov 14
PMID 19910050
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Major histocompatibility complex (MHC) class I and II proteins have been in the focus of interest for immunologists, biochemists, cell biologists, and structural biologists for decades. With dozens of entries in the Protein Data Bank, their crystal structures are now sufficiently well understood, while their dynamic properties such as peptide binding and intracellular trafficking and their immunological (as well as non-immunological) functions are still being intensely investigated. In recent years, new methods and technologies have emerged to detect and characterize the conformational changes and intermediate states that accompany peptide binding and exchange by MHC proteins. These techniques have delivered more detailed information and allowed us to compare the molecular mechanisms of peptide selection between MHC class I and II proteins, suggesting both similarities and differences. Here, we review these recent achievements and suggest avenues for further work.

Citing Articles

Sex differences in Guillain Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy and experimental autoimmune neuritis.

McCombe P, Hardy T, Nona R, Greer J Front Immunol. 2022; 13:1038411.

PMID: 36569912 PMC: 9780466. DOI: 10.3389/fimmu.2022.1038411.


Development of an Immortalized Porcine Fibroblast Cell Panel With Different Swine Leukocyte Antigen Genotypes.

Le Q, Youk S, Choi M, Jeon H, Kim W, Ho C Front Genet. 2022; 13:815328.

PMID: 35198008 PMC: 8859410. DOI: 10.3389/fgene.2022.815328.


Impact of Structural Observables From Simulations to Predict the Effect of Single-Point Mutations in MHC Class II Peptide Binders.

Ochoa R, Laskowski R, Thornton J, Cossio P Front Mol Biosci. 2021; 8:636562.

PMID: 34222328 PMC: 8253603. DOI: 10.3389/fmolb.2021.636562.


Immunoinformatics prediction of potential B-cell and T-cell epitopes as effective vaccine candidates for eliciting immunogenic responses against Epstein-Barr virus.

Olotu F, Soliman M Biomed J. 2021; 44(3):317-337.

PMID: 34154948 PMC: 8358216. DOI: 10.1016/j.bj.2020.01.002.


The dominantly expressed class II molecule from a resistant MHC haplotype presents only a few Marek's disease virus peptides by using an unprecedented binding motif.

Halabi S, Ghosh M, Stevanovic S, Rammensee H, Bertzbach L, Kaufer B PLoS Biol. 2021; 19(4):e3001057.

PMID: 33901176 PMC: 8101999. DOI: 10.1371/journal.pbio.3001057.